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Excessive daytime sleepiness (EDS) is an important
symptom that needs to be quantified. Three tests, the
Multiple Sleep Latency Test (MSLT), the Epworth sleepi-
ness scale (ESS), and the Maintenance of Wakefulness
Test are widely used for this purpose [1]. The MSLT
and ESS are the two most commonly used tests for
evaluating EDS patients at sleep centers worldwide,
including Taiwan. However, MSLT and ESS may not
be closely correlated [1] and there is uncertainty as to
which test is the better tool for evaluating EDS or for
assessing the efficacy of medical therapy of EDS. The
ESS assesses subjective sleepiness while the MSLT
assesses objective sleepiness. The Bureau of National
Health Insurance in Taiwan requires that narcoleptic
patients receiving modafinil therapy must be followed
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This is the first report describing the efficacy of modafinil therapy for narcolepsy in patients in
Taiwan. The purpose of this study was to compare the objective Multiple Sleep Latency Test
(MSLT) and the subjective Epworth Sleepiness Scale (ESS) for evaluating the efficacy of modafinil
in treating excessive daytime sleepiness in patients with narcolepsy in Taiwan. Ten consecutive
patients with narcolepsy-with-cataplexy who were treated with 200 mg/day modafinil for more
than 6 months at our sleep center between January 2003 and December 2007 were included in this
study. This comparative study was prompted by the requirement of the Bureau of National Health
Insurance in Taiwan that modafinil users need to be followed up with MSLTs every 6–12 months.
The mean age at onset of narcolepsy onset in these 10 patients was 11.8 ± 3.3 years, and eight (80%)
were male. We compared the differences in MSLT and ESS between baseline and follow-up at 6–12
months after starting modafinil therapy using paired t tests. ESS scores (p < 0.001) were consider-
ably more sensitive than MSLT scores (p < 0.05) in documenting efficacy of modafinil and that the
improvements in MSLT scores were minimal and remained in the pathologically sleepy range.
These findings suggest that the ESS is a more sensitive and clinically meaningful tool to evaluate
the efficacy of modafinil in narcolepsy.
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up with MSLTs every 6–12 months. Thus the purpose
of this study was to compare the use of the MSLT and
ESS in evaluating the efficacy of modafinil in patients
with narcolepsy.
METHODS
We included a total of 10 consecutive patients with
narcolepsy-with-cataplexy treated at our sleep center
from January 2003 to December 2007 (Tables 1 and 2).
Narcolepsy was diagnosed according to the criteria
established by the International Classification of Sleep
Disorders, Second Edition [2], which included the
following: EDS occurring almost daily for at least 
3 months; a definite history of cataplexy; objective 
confirmation by nocturnal polysomnography (PSG)
followed by a next-day MSLT; mean sleep latency 
on MSLT is ≤ 8 minutes, with two or more sleep-onset
rapid eye movement (REM) periods present in the
MSLT after sufficient nocturnal sleep (minimum 
6 hours) during the preceding nocturnal PSG; and 
hypersomnia is not better explained by another sleep
disorder, neurological disorder, mental disorder,
medication use, or substance use.
A comprehensive questionnaire covering lifetime
sleep–wake, medical and psychiatric history, and a
review of sleeping and medical symptoms was com-
pleted for these 10 patients, which included the Chinese
version of the ESS [3]. Neurological examinations and
psychiatric interviews were also conducted. Brain
magnetic resonance imaging and biochemistry screen-
ing (fasting blood sugar, liver function, renal function
and thyroid function) were also performed. Over-
night, hospital-based, PSG monitoring, using standard
recording and scoring methods [4], was performed
for these 10 patients 8 weeks after discontinuing any
prior medications. The PSG monitoring included eye
movements (electrooculogram); routine electroenceph-
alographic montage; submental and anterior tibialis
electromyograms; oral-nasal airflow, chest and abdo-
men respiratory effort; electrocardiogram; and contin-
uous time-synchronized audiovisual recording. MSLT
was performed every 2 hours, starting after a sponta-
neous morning awakening from the overnight PSG
study. Sleep latency was defined as the time to the
first epoch of stage 2–4 non-REM or REM sleep, or
the first three continuous epochs of stage 1 sleep [4].
After the patients were diagnosed as having nar-
colepsy with cataplexy, modafinil therapy was initi-
ated at a standard dose of 200mg taken every morning.
After 6–12 months of ongoing therapy, all 10 patients
underwent MSLT (after at least 6 hours of nocturnal
sleep) and ESS.
Table 1. Demographic and clinical characteristics of the patients
Age at Age at Symptoms
BMI Patient Sex examination onset 
EDS Cataplexy SP HH (kg/m2) (yr) (yr)
1 M 12 10 + + + – 19.5
2 F 8 6 + + + + 23.8*
3 F 14 11 + + – – 25.0*
4 M 21 11 + + – – 40.0*
5 M 20 17 + + – + 27.7*
6 M 13 9 + + – – 32.3*
7 M 13 12 + + – – 21.6
8 M 18 12 + + – – 22.5
9 M 15 14 + + + + 29.4*
10 M 22 16 + + + – 27.1*
*BMI in the overweight range when compared with normative values for the age group. BMI = Body mass index; EDS = excessive
daytime sleepiness; SP = sleep paralysis; HH = hypnagogic hallucination.
Table 2. Descriptive statistics of the patients (n = 10)*
Sex, female:male 2:8
Age at examination (yr) 15.60 ± 4.50
Age at onset (yr) 11.80 ± 3.26
Treatment duration (mo) 9.60 ± 3.10
*Data presented as mean ± standard deviation.
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RESULTS
Brain magnetic resonance imaging and biochemistry
data were unremarkable in these 10 patients. The PSG
results and baseline (i.e. pretreatment) MSLT and ESS
scores are shown in Table 3. The mean age at nar-
colepsy onset was 11.8 ± 3.3 years, and eight (80%)
patients were male. PSG also identified one patient
(10%) with mild obstructive sleep apnea (Respiratory
Disturbance Index, 16.8/hr, with minimal oxygen
desaturation nadirs of 90–95%), which was managed
with weight loss therapy rather than with continuous
positive airway pressure therapy. Mean body mass
index was 26.9 ± 6.0 kg/m2, which was in the over-
weight range. Four (40%) patients showed modest
periodic limb movement during sleep, as shown in
Table 3, without clinical correlates. No patient had rest-
less legs syndrome. The mean ESS score was 20.0 ± 1.6,
and the mean MSLT sleep latency was 1.7 ± 0.8 
minutes.
Modafinil was taken once daily in the morning by
all 10 patients and was very well tolerated. Treatment-
related adverse experiences were rare and were mostly
mild, including palpitations after intense exercise. No
patient expressed a need to take a dose higher than
the initial dose of 200 mg. After 6–12 months of treat-
ment with 200 mg/day modafinil, all 10 patients un-
derwent MSLT and ESS. At this time, the mean MSLT
sleep latency was 2.2 ± 1.0 minutes and the mean ESS
score was 13.8 ± 3.3. Only one patient received sepa-
rate therapy for cataplexy, consisting of low-dose
25 mg/day imipramine. Many of the patients reported
a substantial improvement in cataplexy with modafinil
therapy (Table 3).
We performed statistical analysis using paired 
t tests for within-subject comparisons and the results
are expressed as mean ± standard deviation (Tables 2
and 4). As shown in Table 4, we found that there were
significant pretreatment versus post-treatment differ-
ences in the mean MSLT sleep latency and ESS scores
in these 10 patients. However, the MSLT sleep latency
scores remained in the pathologically sleepy range.
Therefore, this statistically significant difference does
not reflect a clinically significant change. The difference
in ESS score after modafinil therapy was more signif-
icant compared with the difference in MSLT score. The
changes in ESS score indicate clinically significant ef-
fects of modafinil. Treatment was not associated with
any changes in body mass index, as shown in Table 4.
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DISCUSSION
In this first report on modafinil therapy for narcolepsy
in Taiwan, our MSLT data are consistent with the pre-
viously published results of multicenter studies using
different research designs. There was variable or 
suboptimal improvement in the MSLT latencies with
traditional stimulants used to treat narcolepsy, e.g.
methylphenidate and amphetamine [5,6]. Further-
more, the authors of a controlled PSG study compris-
ing 25 patients with narcolepsy being treated with
traditional stimulants and 25 controls, reported that
“despite taking their usual medications, narcoleptic
subjects averaged 44 minutes of daytime sleep com-
pared with 4.8 minutes for controls… These findings
indicate that daytime sleep episodes were common in
narcoleptic patients who considered their treatment
satisfactory” [7]. In Caucasian populations, “results
from several multicenter studies indicated that mo-
dafinil had a significant impact on the objective meas-
ures of sleepiness; however, the improvement noted
on MSLT was never normalized. This suggests that
narcolepsy is a complex disorder in which the mech-
anisms underlying daytime sleepiness are not yet
well understood” [8]. Our study is the first to report
similar MSLT data in an Asian population (in Taiwan)
of narcoleptic–cataplectic patients, and to support the
use of the ESS for monitoring the longitudinal efficacy
of modafinil therapy in Taiwan.
The ESS is a self-administered questionnaire com-
prising eight items, and is described in more detail
elsewhere [9]. It asks the subject to rate on a four-point
scale his/her chances of dozing in each of eight differ-
ent situations that are often encountered in daily life.
The situations were chosen owing to their potential
ability to induce dozing/sleepiness. The scores for
each item of the ESS provide a measure for one situa-
tion that could induce sleep. The MSLT is a daytime
test that measures how quickly the subject falls asleep
objectively, during five structured nap opportunities
separated by 1.5–2-hour intervals [10]. During each
nap opportunity, the patient is asked to go to bed in a
quiet, darkened bedroom for 20 minutes, while being
monitored by standard PSG equipment. For the MSLT
data to be valid, the patient needs to sleep for a mini-
mum of 6 hours during the preceding nocturnal PSG.
The sleep latency during each nap opportunity is
documented objectively. If the patient does not sleep
then, by definition, the sleep latency for that nap is
scored as 20 minutes. The mean sleep latency is deter-
mined from the sleep latencies identified during the
four (or 5–6) structured nap opportunities.
In a study by Sangal et al [11] of 522 drug-free
patients with narcolepsy, the mean MSLT was 2.8 ± 3.8
minutes, and the mean ESS score was 17.7 ± 3.8. This
is similar to our findings where 10 drug-free patients
with narcolepsy had a mean ESS was 20.00 ± 1.63 and
a mean MSLT of 1.72±0.80 minutes. After our patients
were treated with 200 mg/day modafinil for 6–12
months, the mean MSLT increased to 2.16 ± 0.96 min-
utes and the mean ESS score decreased to 13.80 ± 3.26.
The mean ESS score of 13.8 approximated the norma-
tive score of 12 for the ESS. In contrast, the change in
MSLT sleep latency from 1.72 to 2.16 minutes, although
statistically significant, was not clinically significant,
remaining in the pathologic range. In contrast, the
change in ESS score from 20.0 to 13.8 appears to be
clinically significant and matches the patients’ reports
during follow-up visits on improvements in their
EDS with modafinil therapy. This marked improve-
ment was also reflected by the finding that none of
the patients requested an increase in modafinil dose.
Modafinil is a pharmacologically and clinically
promising compound for the treatment of pathologic
daytime sleepiness found in narcolepsy. Although the
MSLT is the “gold standard” for objectively establish-
ing the presence of daytime sleepiness in narcolepsy,
it has poor sensitivity for measuring improvements in
Table 4. Comparison before and after modafinil treatment*
Before treatment After treatment p†
Body mass index (kg/m2) 26.89 ± 5.99 26.72 ± 3.75 0.890
ESS 20.00 ± 1.63 13.80 ± 3.26 < 0.001
MSLT 1.72 ± 0.80 2.16 ± 0.96 0.020
SOREMP episodes 4.30 ± 0.82 4.10 ± 0.88 0.510
*Data presented as mean ± standard deviation; †Paired t test. ESS = Epworth Sleepiness Scale; MSLT = Multiple Sleep Latency Test;
SOREMP = sleep-onset rapid eye movement period.
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EDS with modafinil therapy or with traditional stim-
ulant therapy for narcolepsy. Therefore, follow-up
MSLT results may be misleading. This may have im-
portant practical implications in Taiwan, where the
Bureau of National Health Insurance requires follow-
up MSLT testing every 6–12 months for narcoleptic
patients receiving modafinil therapy.
The ESS has a major advantage over the MSLT in
terms of its very low cost and ease of administration.
Furthermore, the ESS appears to be quite sensitive and
clinically useful for evaluating the efficacy of modafinil
for narcolepsy.
Some caution is needed when interpreting our find-
ings. First, a placebo effect in the ESS findings may
have been present in this uncontrolled study. The lack
of a control group could at least partly explain the dif-
ferences in ESS and MSLT scores, since a placebo effect
is a subjective effect, and the ESS is a subjective test.
On this basis, the MSLT may be a more accurate reflec-
tion of daytime sleepiness. Second, a higher dose of
modafinil may have affected the results differently
although, as already stated, no patient requested an
increase in modafinil dose. Third, the MSLT and ESS
appear to assess different aspects of narcoleptic sleepi-
ness. The ESS may reflect average daily sleep propen-
sities in the patients’ natural environment, whereas the
MSLT may reflect one situation-specific sleep propen-
sity, i.e. structured naps in the “artificial” environment
of the sleep laboratory. These comments about the
ESS and MSLT are relevant not only to our study, but
also to the studies cited in this discussion regarding
traditional stimulant therapy for narcolepsy.
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葉世彬
1
  Carlos Hugh Schenck
2,3
1
彰化基督教醫院  雲林分院  神經內科暨睡眠中心
2
美國明尼蘇達大學  醫學院  精神科
3
明尼蘇達區域睡眠中心
這是第一個在台灣有關使用 modafinil 治療猝睡症患者的研究報告。這個研究的目的
在於比較客觀的多次入睡潛伏時間測試及主觀的 Epworth 嗜睡量表，何者為評估 
modafinil 治療猝睡症患者的最佳工具，我們自 2003 年 1 月至 2007 年 12 月，共收
集 10 個併有猝倒症狀的猝睡症患者，這 10 個患者皆接受每天 modafinil （200毫
克）的治療超過 6 個月。這個比較性研究的促成乃是基於台灣健保局的規定，凡是使
用 modafinil 治療的猝睡症患者，每 6 至 12 個月皆需要追蹤多次入睡潛伏時間測試
的結果。這 10 個患者的平均發病年齡為 11.8 ± 3.3 歲，80% 為男性。我們利用成
對樣本 t 檢定來比較用藥 6 至 12 個月後，多次入睡潛伏時間測試及 Epworth 嗜睡量
表在使用 modafinil 治療前後有何差異。我們發現 Epworth 嗜睡量表（p < 
0.001），在評估 modafinil 的藥效比多次入睡潛伏時間測試（p < 0.05）更為敏感，
尤其我們也發現多次入睡潛伏時間測試的改善，是相當微不足道的，其測試結果仍停
留在病態嗜睡的範圍內。這些發現讓我們瞭解 Epworth 嗜睡量表比多次入睡潛伏時
間測試，對於評估台灣猝睡症患者的 modafinil 使用療效，在臨床上是一個比較敏感
且具有臨床意義的工具。
關鍵詞：Epworth嗜睡量表，嗜睡症，Modafinil，多次入睡潛伏時間測試，猝睡症
（高雄醫誌 2010;26:422–7）
